Gesellschaftsrecht / M&A

Steuern

Prozesse

Wettbewerb

IP / IT

Homburger News

Homburger and Danaher

On August 19, 2024, Genedata AG announced that it has been acquired by Danaher Corporation (NYSE: DHR), a leading global life science and diagnostic innovator.
Founded in 1997 and headquartered in Basel, Switzerland, Genedata is at the forefront of transforming data into intelligence for the life sciences industry. It delivers scalable and open solutions that enhance R&amp;D productivity, serving top global biopharmaceutical companies and innovative biotechnology organizations around the globe.
The Homburger team advising Danaher comprised Stefan Blunschi, Heinz Schärer, Oriana Schöni, Marilena Balthasar and Paula Delissen (all Corporate / M&amp;A), Reto Heuberger and Philippe Weber (both Tax), Mariella Orelli (Litigation), Richard Stäuber (Competition) and Joel Fink (IP / IT).

Homburger advised Danaher Corporation on its acquisition of Genedata AG

KPMG_web-640x140

Homburger and KPMG

On May 24, 2024, KPMG Switzerland and KPMG UK announced that their respective partnerships had voted overwhelmingly in favor of merging their partnerships, creating a new USD 4.4 bn business, working across audit, tax and legal, and advisory. Both firms enter the merger from positions of strength as growing, profitable businesses in their respective home markets and have a long and strong history of working together for multinational clients. With a wider geographic coverage, the new firm will be able to expand its service and sector expertise complementing the already deep local market understanding for its national and international clients.
Homburger AG acted as legal counsel to KPMG Switzerland on the transaction. The Homburger team was led by Daniel Hasler (Corporate / M&amp;A) and included Thierry Burckhardt, Marc Abplanalp, Paula Delissen, Marilena Balthasar, Norina Tröhler (all Corporate / M&amp;A), Richard Stäuber, Erik Habich (both Competition), and Stefan Oesterhelt (Tax).

Homburger advised KPMG Switzerland on its merger with KPMG UK

Arbeitsrecht und Vergütung für Führungskräfte

addex Therapeutics

Share-Image Teamplate Deals-and-Cases

Homburger advised Addex Therapeutics Ltd

On April 3, 2024, Addex Therapeutics, a clinical-stage biopharmaceutical company, listed on the SIX Swiss Exchange and on the Nasdaq, and funds affiliated with Perceptive Advisors, an investment management firm focused on the life sciences sector, announced the launch of Neurosterix, a company focused on developing allosteric modulators for the treatment of underserved neurological disorders.
With initial funding of USD 63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix acquired a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex in view of accelerating their development. In return, Addex received CHF 5 million and a 20% equity interest in Neurosterix. Addex will retain its partnerships with Janssen Pharmaceuticals, Inc. and Indivior PLC, as well as unpartnered clinical stage assets including dipraglurant for Parkinson’s disease and post-stroke/TBI recovery as well as its preclinical GABAB positive allosteric modulator (PAM) program for chronic cough.
Homburger advised Addex in this transaction. The Homburger team comprised Frank Gerhard, Romain Fakhoury, Fabio Gasser, Paula Delissen (all Corporate / M&amp;A), Jeremy Reichlin (Employment) and Peter Müller (Tax).

Homburger advised Addex Therapeutics Ltd (SIX and Nasdaq: ADXN) on the launch of Neurosterix

Paula
Delissen

Homburger advised Danaher Corporation on its acquisition of Genedata AG

Homburger advised KPMG Switzerland on its merger with KPMG UK

Homburger advised Addex Therapeutics Ltd (SIX and Nasdaq: ADXN) on the launch of Neurosterix

Join the Team

Paula Delissen

Karriere

Sprachen

Zulassung

Teams

PaulaDelissen

Homburger advised Danaher Corporation on its acquisition of Genedata AG

Homburger advised KPMG Switzerland on its merger with KPMG UK

Homburger advised Addex Therapeutics Ltd (SIX and Nasdaq: ADXN) on the launch of Neurosterix

Join the Team

Paula Delissen

Karriere

Sprachen

Zulassung

Teams

Paula
Delissen